Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Predictive Oncology Inc.’s (NASDAQ: POAI) Subsidiary a ‘Major Asset’ in Growing Precision Medicine Space

  • POAI addresses pressing need for a multi-omic approach in field of precision medicine
  • Global precision medicine market is expected to reach total market value of approximately $84 billion by 2026
  • Predictive Oncology’s ‘claim to fame’ is its inventory of over 150,000 tumors covering over 137 types of cancer, with over 30,000 related to ovarian cancer

In the burgeoning world of precision medicine, Predictive Oncology Inc. (NASDAQ: POAI) appears ideally positioned to address one of the most pressing problems in the industry: the need for a multi-omic approach to precision therapy that may offer markedly improved patient outcomes over just genomics alone. POAI, a leader in the cancer precision-medicine field, has a “major asset” in its Helomics subsidiary, which specializes in ovarian cancer. Through its unique patient derived (PDx) platform, which tests the drug response and biomarker profile of the patient’s own tumor, and its vast database of historical tumor profiles, Helomics provides clinical decision support tools today to assist oncologists in individualizing cancer treatment.

Precision medicine is based on the idea of customizing health care, making medical decisions and selecting treatments, practices and prescriptions that are tailored to each individual patient rather than a recommended general treatment approach. A recent Acumen Research and Reporting article noted that the global precision medicine market is expected to reach total market value of approximately $84 billion by 2026 with anticipated CAGR growth of around 10% in terms of revenue between 2019 and 2026 (http://ibn.fm/vufVR).

That growth hasn’t gone unnoticed. Big pharma has invested heavily in precision medicine, focusing its efforts on genomics and “big data” to understand each patient’s genome in order to deliver targeted therapeutics. “Success rates for these targeted therapies are low, and uptake in clinical practice is patchy,” POAI reports on its website (http://ibn.fm/MywNK), noting a growing realization that “just genomics is not enough to achieve the promise of personalized therapeutics. A clear need has emerged for a multi-omic approach that may offer a much greater chance of success. However, few comprehensive, multi-omic data sets exist, and such data is difficult to access quickly as it is both costly and time consuming to initiate prospective data collection — especially in cancer.”

Multiomics, or the use of multiple omics technologies (i.e., genome, proteome, transcriptome, epigenome, microbiome, etc.) to study disease in a more comprehensive manner has significant implications in the world of health care – and Predictive Oncology owns powerful data and technology that may make the company a clear frontrunner in the precision medicine space.

“Predictive’s major asset is its subsidiary Helomics, and its claim to fame is its inventory of over 150,000 tumors covering over 137 types of cancer, with over 30,000 related to ovarian cancer, which is sort of our specialty. In fact, this is the largest inventory of its kind in the world,” POAI director and CEO Carl Schwartz stated in a news release (http://ibn.fm/e9EIC).

Furthermore, the data in POAI’s molecular information platform are highly differentiated, the company explained, containing both drug-response and biomarker data and with access to historical outcome data from these individual patients. Predictive Oncology is working to gather additional sequence data (mutation and gene expression) from these tumor samples, coupling this with its unique drug response profiles to build AI-driven predictive models of cancer that it believes will meet the unmet market need for a multi-omic approach to the development of new drugs and improve patient outcomes.

POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through the company’s Helomics division, the company leverages its unique, clinically validated patient derived (PDx) smart tumor profiling platform to provide oncologists with a road map to help individualize therapy.

In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow

For more information, visit the company’s website at www.Predictive-Oncology.com

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

This entry was posted in Predictive Oncology Inc. POAI. Bookmark the permalink.

Comments are closed.